The Cigna Group / Express Scripts: enforcement record and regulatory exposure
The Cigna Group / Express Scripts scores 57 out of 100 on the RedFlag Index™ (October 2026), ranking #6 of ten tracked companies, with 4 documented cases of which 3 remain open.
Documented record
2023: Cigna paid $172.3 million under the False Claims Act for submitting inaccurate Medicare Advantage diagnosis codes, with factual admissions.
Cigna is under a five-year corporate integrity agreement until about September 2028.
RegulationWatch coverage
- PBM Rebates
Express Scripts settled the insulin case without paying a cent or admitting a thing.
The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.
- PBM Rebates
Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.
Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.
- Drug Pricing
Fruth reimbursement claims move to arbitration and Missouri federal court
A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.
- Drug Pricing
Arkansas pharmacies sue Express Scripts over alleged reimbursement floor violations
Twelve Arkansas pharmacies filed a private lawsuit against Express Scripts in Missouri state court, alleging reimbursements below Arkansas's statutory minimum. They seek damages and court-ordered changes; the filing establishes no liability.
- Medicare Advantage
Cigna was accused of billing Medicare for diagnoses it could not support. It paid $172.3 million.
The settlement includes no admission. Cigna's review found unsupported codes and it left them in place, the government said.
- PBM Rebates
Sixth Circuit keeps Kentucky opioid case against PBMs in federal court
The Sixth Circuit reversed an order returning Kentucky's opioid lawsuit against Express Scripts and OptumRx to state court. The ruling addressed jurisdiction, without deciding liability.
- PBM Rebates
Louisiana files federal antitrust suit against Express Scripts and Ascent Health Services
Louisiana Attorney General Liz Murrill has sued Express Scripts, Inc. and its group purchasing affiliate Ascent Health Services LLC in federal court, alleging a conspiracy with Prime Therapeutics to fix pharmacy reimbursement rates. The complaint also alleges that manufacturer rebates were reclassified as fees and that patients were steered to Express Scripts-affiliated pharmacies.
- Antitrust
Florida sues Prime Therapeutics and Express Scripts over alleged pharmacy price-fixing
Florida Attorney General James Uthmeier has sued Prime Therapeutics LLC and Express Scripts, Inc., alleging the two pharmacy benefit managers entered a horizontal price-fixing agreement that cut reimbursements to Florida pharmacies. The state seeks injunctive relief, civil penalties, disgorgement and damages.
- Opioid Litigation
Kentucky's opioid case against two PBMs is going to federal court. Its allegations are still unanswered.
A Sixth Circuit ruling settles where the case is heard. Two years after Kentucky sued, no court has tested what Express Scripts and Optum actually did.
- FTC Enforcement
FTC pauses OptumRx insulin case to weigh proposed consent agreement
The Federal Trade Commission withdrew its insulin pricing case against UnitedHealth's OptumRx and its affiliate Emisar from adjudication to consider a proposed consent agreement. The agreement has been approved by the directors of the FTC's competition and consumer protection bureaus but still requires Commission approval, and its terms have not been disclosed.
- PBM Rebates
Missouri sues 19 PBMs and insulin makers over alleged pricing scheme
Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.
- Drug Pricing
Oregon seeks $900 million from insulin makers and PBMs over pricing
Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.
- PBM Rebates
CVS Caremark becomes second major PBM to settle FTC insulin rebating case
The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.
- FTC Enforcement
FTC settles insulin rebate case with Cigna's Express Scripts under sweeping consent order
The Federal Trade Commission settled its insulin rebating case against Express Scripts, the Cigna-owned pharmacy benefit manager. The consent order requires formulary, compensation and transparency changes that the FTC estimates will save patients up to $7 billion in out-of-pocket costs over ten years.
- FTC Report
FTC interim report finds three PBMs control nearly 80% of US prescriptions amid rebate scrutiny
The FTC's first interim staff report on pharmacy benefit managers found that the three largest PBMs processed nearly 80% of the 6.6 billion prescriptions dispensed in the US in 2023. The report documented vertical integration with insurers and specialty pharmacies and found PBM-affiliated pharmacies charging substantially higher prices than independents for the same drugs.
